NuCana plc (NCNA) Stock Price, Financials & Summary

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.0x

Market Cap

$5.87M

MomentumView details →

1D Return

−1.40%

YTD Return

−60.83%

RSI (14)

46.8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.0x

Market Cap

$5.87M

RSI (14)

46.8

MomentumView details →

1D Return

−1.40%

YTD Return

−60.83%

SummaryUpdated Jun 1, 2026

NuCana plc (NASDAQ:NCNA) is a clinical-stage biopharmaceutical company founded in 1997 and headquartered in Edinburgh, United Kingdom. The company went public in September 2017, transitioning from its former name NuCana BioMed Limited. NuCana focuses on developing innovative cancer treatments using its proprietary ProTide technology platform, with multiple drug candidates currently progressing through various phases of clinical trials for treating solid tumors and blood cancers.

Ask drillr about NuCana plc →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−48.30%

ROA (TTM)

−37.96%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+90.90%

FCF YoY

+74.06%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+98.95%

EBITDA YoY

+29.53%

EarningsView details →

EPS (Actual)

−$0.99

EPS Surprise

62.66%

Beats (12Q)

7/12

Next Q EPS Est

−$2.74

Avg Surprise (4Q)

64.28%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

4.73x

Quick Ratio

4.73x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−9.73M

Op. CF (TTM)

−4.98M

Next earningsNov 12, 2026 →

Latest newsMore news →

No recent news for NCNA.

Similar companies

Dermata Therapeutics, Inc.DRMA Processa Pharmaceuticals, Inc.PCSA XTL Biopharmaceuticals Ltd.XTLB Cardio Diagnostics Holdings, Inc.CDIO GRI Bio, Inc.GRI HCW Biologics Inc.HCWB Find similar companies →

Latest newsMore news →

No recent news for NCNA.